2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2
  • HY-134809
    Cyclotriazadisulfonamide 182316-44-5 98.45%
    Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor.
    Cyclotriazadisulfonamide
  • HY-136211
    Cystathionine-γ-lyase-IN-1 2165706-30-7 ≥99.0%
    Cystathionine-γ-lyase-IN-1 is a selective cystathionine γ-lyase (CSE) enzyme inhibitor with an IC50 of 6.3 μM. Cystathionine-γ-lyase-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Cystathionine-γ-lyase-IN-1
  • HY-137255
    Taurolithocholic acid 3-sulfate disodium 64936-83-0 ≥99.0%
    Taurolithocholic acid 3-sulfate disodium is a GPR39 agonist with EC50s of 71.6  and 69.4 (absence of Zn2+) and 9 and 9.6 μM (presence of Zn2+) in M39-20 and hGPR39-2 cells, respectively. Taurolithocholic acid 3-sulfate disodium stimulates GPR39 receptors to initiate intracellular calcium signaling, independent of Zn2+ binding sites H17 and H19. Taurolithocholic acid 3-sulfate disodium can be used for the research of gallbladder disease.
    Taurolithocholic acid 3-sulfate disodium
  • HY-149874
    BMS-502 2407854-18-4 ≥99.0%
    BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research.
    BMS-502
  • HY-150608
    PROTAC STING Degrader-1 2762552-74-7 98.26%
    PROTAC STING Degrader-1 is a PROTAC degrader targeting the STING pathway with a DC50 of 3.2 μM. PROTAC STING Degrader-1 exerts high anti-inflammatory efficacy. PROTAC STING Degrader-1 can be used to study diseases such as acute kidney injury and inflammatory bowel diseases (IBDs).
    PROTAC STING Degrader-1
  • HY-156406
    PITCOIN4 3032439-98-5 99.97%
    PITCOIN4 is a highly selective Class II Alpha PI3K-C2α inhibitor. PITCOIN4 shows nanomolar inhibition of PI3K-C2α and >100-fold selectivity in a general kinase panel.
    PITCOIN4
  • HY-156907
    ZINC49534341 1274013-03-4 99.40%
    ZINC49534341 is a MRGPRX2 antagonist, with a Ki of 32 nM.
    ZINC49534341
  • HY-172371
    Hypoxystat 2414508-40-8 99.28%
    Hypoxystat is an orally active hypoxia mimetic. HypoxyStat increases Hemoglobin’s oxygen affinity, limiting oxygen offloading to the tissues and inducing local tissue hypoxia. Hypoxystat reduces Iba1+ cells. HypoxyStat causes systemic hypoxia. Hypoxystat effectively rescues hyperglycemia in mouse models of type 1 and type 2 diabetes. HypoxyStat not only extends lifespan but also rescues key neuropathological and behavioral deficits in the premier mouse model of Leigh syndrome.
    Hypoxystat
  • HY-17589R
    Chloroquine phosphate (Standard) 50-63-5 99.67%
    Chloroquine (phosphate) (Standard) is the analytical standard of Chloroquine (phosphate). This product is intended for research and analytical applications. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
    Chloroquine phosphate (Standard)
  • HY-N0592A
    Demethyleneberberine chloride 16705-03-6 98.90%
    Demethyleneberberine chloride is a blood-brain barrier-permeable antioxidant. Demethyleneberberine chloride exerts antioxidant effects by targeting mitochondria, activates the AMPK signaling pathway to regulate lipid metabolism, and inhibits inflammation-related pathways such as NF-κB and MAPK. Demethyleneberberine chloride can be used in the research of inflammatory and other diseases.
    Demethyleneberberine chloride
  • HY-P0298A
    [Des-Arg9]-Bradykinin acetate 23827-91-0 99.87%
    [Des-Arg9]-Bradykinin acetate is a Bradykinin B1 receptor agonist that displays selectivity for B1 over B2 receptors.
    [Des-Arg9]-Bradykinin acetate
  • HY-P10375
    BMS-986189 1629665-96-8 99.58%
    BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987.
    BMS-986189
  • HY-P10739
    WYRGRL 1021155-39-4 99.88%
    WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis.
    WYRGRL
  • HY-P99646
    Golocdacimab 2418540-63-1 99.11%
    Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.
    Golocdacimab
  • HY-111615A
    J-2156 TFA 2387505-73-7 99.88%
    J-2156 TFA is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.
    J-2156 TFA
  • HY-P990151
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6)
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonal antibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA).
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6)
  • HY-W002879
    4-Hydroxyphenylboronic acid pinacol ester 269409-70-3 ≥98.0%
    4-Hydroxyphenylboronic acid pinacol ester is a ROS-responsive component. 4-Hydroxyphenylboronic acid pinacol ester can structurally modify hyaluronic acid to prepare ROS-responsive intelligent nanocarriers and compound delivery systems. 4-Hydroxyphenylboronic acid pinacol ester endows hyaluronic acid-based nanocarriers with ROS responsiveness, enabling them to rapidly release the encapsulated Curcumin (HY-N0005) in the presence of reactive oxygen species. 4-Hydroxyphenylboronic acid pinacol ester is applicable to research related to periodontitis. 4-Hydroxyphenylboronic acid pinacol ester can also be used for the synthesis of boronic acid-modified resins.
    4-Hydroxyphenylboronic acid pinacol ester
  • HY-W010255
    Phenylglyoxylic acid 611-73-4 99.66%
    Phenylglyoxylic acid (Benzoylformic acid) is a metabolite of ethylbenzene and styrene (EB/S) and can be used as a biomarker of exposure to EB/S in human. Phenylglyoxylic acid can be used as drug intermediate for synthesis of antineoplastic compounds.
    Phenylglyoxylic acid
  • HY-W010820
    Uridine 5'-diphosphate sodium salt 21931-53-3 98.0%
    Uridine 5'-diphosphate sodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52) and a potent P2Y14 antagonist (pEC50=7.28). Uridine 5'-diphosphate sodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis.
    Uridine 5'-diphosphate sodium salt
Cat. No. Product Name / Synonyms Application Reactivity